2021
Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
Chouairi F, Pacor J, Miller PE, Fuery MA, Caraballo C, Sen S, Leifer ES, Felker GM, Fiuzat M, O’Connor C, Januzzi JL, Friedman DJ, Desai NR, Ahmad T, Freeman JV. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations Quality & Outcomes 2021, 5: 447-455. PMID: 33997640, PMCID: PMC8105522, DOI: 10.1016/j.mayocpiqo.2021.02.005.Peer-Reviewed Original ResearchNT-proBNP levelsReduced ejection fractionAtrial fibrillationHF hospitalizationHeart failureEjection fractionMedical therapyN-terminal pro-B-type natriuretic peptideOptimal guideline-directed medical therapyPro-B-type natriuretic peptideGuideline-directed medical therapyHigher NT-proBNP concentrationsHigher NT-proBNP levelsGUIDE-IT trialMedical therapy useHeart failure outcomesHeart Failure TrialPrevalent atrial fibrillationNT-proBNP concentrationsType natriuretic peptideEvidence-based therapiesCardiovascular deathAF patientsTherapy useFailure Trial
2013
Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure
Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure. Circulation Cardiovascular Quality And Outcomes 2013, 6: 525-533. PMID: 24021697, DOI: 10.1161/circoutcomes.111.000079.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overCaliforniaCardiotonic AgentsChi-Square DistributionDigoxinDisease ProgressionDrug Therapy, CombinationFemaleGuideline AdherenceHealth Maintenance OrganizationsHeart Failure, SystolicHospitalizationHumansIncidenceMaleMiddle AgedMultivariate AnalysisPractice Guidelines as TopicProportional Hazards ModelsRisk FactorsSex FactorsTime FactorsTreatment OutcomeConceptsIncident systolic heart failureSystolic heart failureSafety of digoxinΒ-blocker useDigoxin useHeart failureHF hospitalizationConcurrent β-blocker useSymptomatic systolic heart failureKaiser Permanente Northern CaliforniaHF disease severityOptimal medical therapyRisk of deathMedical therapyMultivariable analysisContemporary cohortCox regressionClinical guidelinesMedical historyHigh riskHospitalizationHigh mortalityPatientsDisease severityTrial data